Ameriprise
CELL

Ameriprise’s PhenomeX Inc. Common Stock CELL Stock Holding History

Ameriprise’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-72,166
Closed -$83.7K – 4029
2023
Q1 		$83.7K Sell
72,166
-53,665
-43% -$98.1K ﹤0.01% 3845
2022
Q4 		$338K Sell
125,831
-665
-0.5% -$1.75K ﹤0.01% 3547
2022
Q3 		$362K Buy
+126,496
New +$538K ﹤0.01% 3509
2022
Q1 		– Sell
-39,384
Closed -$716K – 4051
2021
Q4 		$716K Buy
39,384
+7,414
+23% +$160K ﹤0.01% 3395
2021
Q3 		$625K Buy
31,970
+2,734
+9% +$104K ﹤0.01% 3330
2021
Q2 		$1.31M Buy
29,236
+9,999
+52% +$464K ﹤0.01% 3107
2021
Q1 		$966K Sell
19,237
-1,056
-5% -$72K ﹤0.01% 3161
2020
Q4 		$1.81M Sell
20,293
-233,118
-92% -$19.6M ﹤0.01% 2843
2020
Q3 		$19.4M Buy
+253,411
New +$16.1M 0.01% 1092

Other funds holding CELL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
NIMC
Nierenberg Investment Management Company Camas, Washington $201M AUM 36.3% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise's CELL Position: Q2 2023 in Review

Ameriprise sold out of PhenomeX Inc. Common Stock (CELL) in Q2 2023, closing a stake of 72,166 shares — an estimated $83.7K sold.

Ameriprise first reported a position in CELL in Q3 2020 and held it in 9 quarters. The position peaked at $19.4M in Q3 2020. 84 funds tracked by Wall St. Rank hold CELL as of Q2 2023.

  • Ameriprise reported no remaining PhenomeX Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ameriprise sold 72,166 PhenomeX Inc. Common Stock shares in Q2 2023, an estimated $83.7K.
  • Ameriprise first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Ameriprise's PhenomeX Inc. Common Stock position peaked at $19.4M in Q3 2020.
  • 84 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.